Losmapimod has the potential to be the first drug to treat FSHD The much-anticipated Phase 3 clinical trial of losmapimod has formally begun with the dosing of the first volunteer,… Read More »
First patient enrolls in Fulcrum’s Phase 3 clinical trial
We are convening the world this month in Orlando, Florida
Global stakeholders are meeting at FSHD Society conferences The FSHD Society is holding back-to-back meetings this month in Orlando, Florida, to convene patients, families, researchers, clinicians, advocacy leaders, industry scientists,… Read More »
Collaborating to collect clinical trial data
FSHD Society and Critical Path Institute will aggregate data in C-Path’s Rare Diseases Cures Accelerator-Data and Analytics Platform The FSHD Society announced that it has partnered with Critical Path Institute… Read More »
Applying AI to FSHD research
Using Artificial Intelligence to Analyze FSHD Data The FSHD Society announced that it is launching a collaboration involving the FSHD Clinical Trial Research Network (CTRN) and BullFrogAI, an innovator in… Read More »
ACT to improve quality of life
by Kent Drescher, PhD, Bay Area Chapter Co-Director I’ve had FSHD symptoms for over 50 years. It seems like I’ve spent much of that time waiting. Waiting for treatment. Waiting… Read More »